Gene test may predict chemo side effects in breast cancer patients

NCT ID NCT00953537

Completed Knowledge-focused Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at whether a deficiency in the DPD enzyme can predict severe side effects from the chemotherapy drug capecitabine in women with metastatic breast cancer. Researchers analyzed blood samples from 303 participants to see if genetic differences could help doctors plan safer treatment. The goal was to reduce risks like diarrhea and hand-foot syndrome by identifying vulnerable patients beforehand.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: capecitabine
What this could lead to: If successful, this could help doctors identify patients at risk for severe side effects from capecitabine, allowing safer, more personalized treatment plans.
What could go wrong: This is a small, completed pilot study, so results may not apply broadly. The focus is on predicting toxicity, not improving outcomes, and the approach may not be ready for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, 06189, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.